"The potential of our novel dual-switch CAR-T platform to provide in vivo control over adoptive immunotherapies is very exciting," said Bellicum's President & CEO Rick Fair. "These data suggest the potential to significantly reduce toxicities while prolonging efficacy using molecular switches activated by small molecule agents. We believe this technology may address some of the major challenges with CAR-T therapies, particularly when targeting solid tumors. We look forward to initiating clinical trials in 2019 with two CAR-T cell candidates engineered with dual switches."
Title: HER2-Targeted Dual-Switch CAR-T Cells Enable Post-Infusion Control of CAR-T Efficacy and Safety with Small Molecules
Session: 113 Cancer - Targeted Gene & Cell Therapy I
Date/Time: Wednesday, May 16th 11:00 a.m. CDT
The presentation will be made available in the Events and Presentations section of the Bellicum website shortly after the presentation.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "designed," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to our dual switch, CAR-T and TCR programs; the effectiveness, their possible ranges of application and potential curative effects and safety in the treatment of diseases, including as compared to other treatment options and competitive therapies; the timing and success of our current and planned clinical trials, including the timing of receipt of data from such clinical trials and the timing of our reports of such data; the expansion of or changes to our ongoing clinical trials to new indications and diseases; our research and development activities; the presentation of our preclinical and clinical data. Various factors may cause differences between Bellicum's expectations and actual results as discussed in greater detail under the heading "Risk Factors" in Bellicum's filings with the Securities and Exchange Commission, including without limitation our quarterly report on Form 10-Q for the three months ended March 31, 2018 and our annual report on Form 10-K for the year ended December 31, 2017.
Source: Bellicum Pharmaceuticals
To read more Press Release articles, click here.